Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide
- 26 September 2004
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 10 (10) , 1128-1132
- https://doi.org/10.1038/nm1111
Abstract
The JNK pathway is known to be activated in several tissues in the diabetic state, and is possibly involved in the development of insulin resistance and suppression of insulin biosynthesis. Here we show a potential new therapy for diabetes using cell-permeable JNK-inhibitory peptide. Intraperitoneal administration of the peptide led to its transduction into various tissues in vivo, and this treatment markedly improved insulin resistance and ameliorated glucose tolerance in diabetic mice. These data indicate that the JNK pathway is critically involved in diabetes and that the cell-permeable JNK-inhibitory peptide may have promise as a new therapeutic agent for diabetes.Keywords
This publication has 25 references indexed in Scilit:
- Targeting JNK for therapeutic benefit: from junk to gold?Nature Reviews Drug Discovery, 2003
- A central role for JNK in obesity and insulin resistanceNature, 2002
- Involvement of c-Jun N-terminal Kinase in Oxidative Stress-mediated Suppression of Insulin Gene ExpressionJournal of Biological Chemistry, 2002
- Mammalian MAP kinase signalling cascadesNature, 2001
- Signal Transduction by the JNK Group of MAP KinasesPublished by Elsevier ,2000
- In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the MouseScience, 1999
- Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migrationNature Medicine, 1998
- Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural ProteinCell, 1997
- JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domainPublished by Elsevier ,1994
- Cellular uptake of the tat protein from human immunodeficiency virusCell, 1988